Navigation Links
Cytochroma announces appointment of Ulrik Spork to Board of Directors
Date:10/30/2008

MARKHAM, ON, Oct. 30 /PRNewswire/ - Cytochroma today announced the appointment of Ulrik Spork to its Board of Directors. Mr. Spork will represent Novo A/S on the Company's Board and replaces Dr. Soren Schifter, who is leaving Novo A/S. The number of Board members remains unchanged at six members.

"We are very pleased to welcome Ulrik Spork to our board and look forward to drawing on his expertise and experiences as we continue building Cytochroma into a leading CKD-focused specialty pharmaceutical company," stated Alan Lewis, Ph.D., Chairman of Cytochroma's Board of Directors. "We would also like to thank Soren Schifter for his advice to Cytochroma over the years, and wish him well in the future."

Ulrik Spork has significant experience in corporate strategy, business development, M&A, product development, and international marketing. As Senior Partner, he led the establishment of venture investment activities by Novo A/S from its inception in 1999. Prior to the formation of Novo A/S, Mr. Spork was Director of Corporate Development at Novo Nordisk A/S, during which he was involved in that company's strategic planning and managed a number of acquisitions. He holds an MSc in Engineering from the Technical University of Copenhagen and a BSc in International Economics.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company's vitamin D-based therapeutics are designed to safely and effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in these same patients. For more information, please visit http://www.cytochroma.com.


'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
6. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... TRIANGLE PARK, N.C. , June 1, 2015 ... announced the presentation of positive interim results from ... SIOPEL6: A multi-centre open label randomised phase III ... in reducing ototoxicity in patients receiving cisplatin (Cis) ... was presented at the American Society of Clinical ...
(Date:6/1/2015)... Resverlogix Corp. (TSX: RVX) (the "Company") today announced that  ... Congress in London, England in ... BET-Inhibitor, on Key Renal Parameters in Subjects with a ... Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ... Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension at University ...
(Date:6/1/2015)... N.Y. , June 1, 2015 /PRNewswire/ ... ) announced today that it has signed ... LLC to co-market their structure-based drug discovery ... As part of the three-year agreement, AMRI ... structure-determination expertise and capabilities. HarkerBIO,s customers will ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... Amicus Therapeutics (Nasdaq: FOLD ) will announce ... of markets on Thursday, May 7, 2009. The results ... and webcast that afternoon at 5 p.m. EDT. Interested ... 5 p.m. EDT by dialing 877-874-1565 (U.S./Canada) or 719-325-4830 ...
... Microfluidics and Imaging -- Net Loss Narrowed by $0.07 per ... (Nasdaq: CALP ) today reported its first quarter ... million compared to $29.3 million in the first quarter of ... 2008 included $2.9 million of revenue related to product lines ...
... of its fifth Best Practices Awards program. Grand Prize winners ... Broad Institute of MIT and Harvard, Genedata, Genentech, GlaxoSmithKline, Merck & ... Research. , ... Needham, Mass (PRWEB) April 29, 2009 ...
Cached Biology Technology:Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date 2Caliper Life Sciences Reports First Quarter 2009 Results 2Caliper Life Sciences Reports First Quarter 2009 Results 3Caliper Life Sciences Reports First Quarter 2009 Results 4Caliper Life Sciences Reports First Quarter 2009 Results 5Caliper Life Sciences Reports First Quarter 2009 Results 6Caliper Life Sciences Reports First Quarter 2009 Results 7Caliper Life Sciences Reports First Quarter 2009 Results 8Caliper Life Sciences Reports First Quarter 2009 Results 9Caliper Life Sciences Reports First Quarter 2009 Results 10Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 2Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 3Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 4Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 5Bio-IT World Announces the Winners of its 2009 Best Practices Awards Program 6
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Meeting on Acoustics -- a major international acoustics conference ... Coral Beach Hotel in Cancun, Mexico. Reporters are invited ... http://www.acoustics.org/press The press room contains news releases ... more than a thousand presentations at the meeting, which ...
... With so few Americans consuming the recommended amounts of fruit ... fruit servings and the important nutrients they provide ... of 100 percent juice supplies one serving (1/2 cup) of ... New research presented today at the American Dietetic Association (ADA) ...
... UNC scientists describes how cells infected by the Epstein-Barr ... changing their cellular "cargo" of proteins and RNA. This ... of recipient cells from benign to cancer-producing. In ... potentially manipulate other cells throughout the body. The findings ...
Cached Biology News:Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 2Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 3Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 4Worldwide press room opens for major acoustical science and technology conference, Nov. 15-19 5Drinking 100 percent fruit juice is linked to higher intake of essential nutrients 2UNC scientists identify cellular communicators for cancer virus 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... 2/3D Waver Shaker combines shaking and rocking for ... 330 x 330 mm stainless steel or acrylic ... and cold room operation. The platform angle is ... a vigorous with action and rotation speed of ...
... kit for 25 chips provides the chips ... analysis (at picogram levels) with the Experion ... RNA HighSens microfluidic chips, 2 x 1,250 ... RNA HighSens stain, 20 microliters RNA ladder, ...
Biology Products: